Epilepsy — Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome
Citation(s)
A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome